Sentiment-Signal
21,9
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointme |
| 23.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 07.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Unternehmen & Branche
| Name | Kiniksa Pharmaceuticals International, plc |
|---|---|
| Ticker | KNSA |
| CIK | 0001730430 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,96 Mrd. USD |
| Beta | 0,06 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 677,564,000 | 59,005,000 | 0.75 | 763,633,000 | 567,606,000 |
| 2025-09-30 | 10-Q | 180,855,000 | 18,435,000 | 0.23 | 712,333,000 | 535,383,000 |
| 2025-06-30 | 10-Q | 156,797,000 | 17,832,000 | 0.23 | 661,150,000 | 495,007,000 |
| 2025-03-31 | 10-Q | 137,785,000 | 8,539,000 | 0.11 | 599,326,000 | 457,489,000 |
| 2024-12-31 | 10-K | 423,239,000 | -43,193,000 | -0.60 | 580,553,000 | 438,436,000 |
| 2024-09-30 | 10-Q | 112,214,000 | -12,693,000 | -0.18 | 555,298,000 | 437,006,000 |
| 2024-06-30 | 10-Q | 108,631,000 | -3,908,000 | -0.06 | 542,428,000 | 435,095,000 |
| 2024-03-31 | 10-Q | 79,858,000 | -17,704,000 | -0.25 | 519,673,000 | 431,895,000 |
| 2023-12-31 | 10-K | 270,259,000 | 14,084,000 | 0.20 | 526,322,000 | 438,839,000 |
| 2023-09-30 | 10-Q | 67,046,000 | -13,855,000 | -0.20 | 483,063,000 | 405,127,000 |
| 2023-06-30 | 10-Q | 71,473,000 | 14,972,000 | 0.21 | 484,332,000 | 411,656,000 |
| 2023-03-31 | 10-Q | 48,345,000 | -12,270,000 | -0.18 | 442,862,000 | 390,095,000 |
| 2022-12-31 | 10-K | 220,180,000 | 183,363,000 | 2.60 | 459,672,000 | 396,149,000 |
| 2022-09-30 | 10-Q | 99,135,000 | 224,093,000 | 3.18 | 459,953,000 | 384,008,000 |
| 2022-06-30 | 10-Q | 26,972,000 | -19,981,000 | -0.29 | 210,576,000 | 153,494,000 |
| 2022-03-31 | 10-Q | 32,189,000 | -25,210,000 | -0.36 | 230,965,000 | 166,244,000 |
| 2021-12-31 | 10-K | 38,544,000 | -157,924,000 | -2.30 | 232,800,000 | 185,037,000 |
| 2021-09-30 | 10-Q | 12,095,000 | -30,544,000 | -0.44 | 252,859,000 | 214,048,000 |
| 2021-06-30 | 10-Q | 7,704,000 | -41,563,000 | -0.61 | 279,208,000 | 235,785,000 |
| 2021-03-31 | 10-Q | -49,484,000 | -0.72 | 311,158,000 | 270,696,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-09 | Moat Ross | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -1,703 | 46.69 | -79,513.07 | -10,7% | |
| 2026-04-09 | Megna Michael R | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -6,625 | 46.69 | -309,321.25 | -41,5% | |
| 2026-03-09 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -18,741 | 46.24 | -866,583.84 | -116,3% | |
| 2026-03-09 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -17,981 | 45.58 | -819,573.98 | -110,0% | |
| 2026-03-02 | Paolini John F. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -12,063 | 44.20 | -533,184.60 | -71,6% | |
| 2026-03-02 | Paolini John F. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -22,223 | 44.88 | -997,368.24 | -133,9% | |
| 2026-03-02 | Paolini John F. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,714 | 45.92 | -262,386.88 | -35,2% | |
| 2026-02-12 | Quart Barry D | Director | Open Market Sale | -2,690 | 45.00 | -121,050.00 | -16,3% | |
| 2026-02-10 | Quart Barry D | Director | Open Market Sale | -110 | 45.00 | -4,950.00 | -0,7% | |
| 2026-02-09 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -9,114 | 42.85 | -390,534.90 | -52,4% | |
| 2026-02-09 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -8,731 | 43.72 | -381,719.32 | -51,2% | |
| 2026-02-04 | Quart Barry D | Director | Open Market Sale | -2,602 | 45.02 | -117,142.04 | -15,7% | |
| 2026-02-03 | Quart Barry D | Director | Open Market Sale | -12,528 | 45.27 | -567,142.56 | -76,1% | |
| 2026-02-02 | Quart Barry D | Director | Open Market Sale | -830 | 45.00 | -37,350.00 | -5,0% | |
| 2026-01-08 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -12,000 | 41.89 | -502,680.00 | -67,5% | |
| 2025-12-15 | Quart Barry D | Director | Open Market Sale | -20,129 | 41.51 | -835,554.79 | -112,2% | |
| 2025-12-15 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -12,048 | 41.56 | -500,714.88 | -67,2% | |
| 2025-12-08 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -42,841 | 41.49 | -1,777,473.09 | -238,6% | |
| 2025-11-26 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -200 | 42.89 | -8,578.00 | -1,2% | |
| 2025-11-17 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -645 | 40.08 | -25,851.60 | -3,5% | |
| 2025-11-17 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -11,825 | 41.30 | -488,372.50 | -65,6% | |
| 2025-11-12 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -19,900 | 40.94 | -814,706.00 | -109,4% | |
| 2025-10-31 | Paolini John F. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -82,542 | 37.14 | -3,065,609.88 | -411,6% | |
| 2025-10-28 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -100 | 41.00 | -4,100.00 | -0,6% | |
| 2025-10-22 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -97,390 | 38.83 | -3,781,653.70 | -507,7% | |
| 2025-10-21 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -39,331 | 38.77 | -1,524,862.87 | -204,7% | |
| 2025-10-20 | Megna Michael R | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -37,255 | 38.72 | -1,442,513.60 | -193,7% | |
| 2025-10-20 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -98,934 | 38.81 | -3,839,628.54 | -515,5% | |
| 2025-10-20 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -22,314 | 39.32 | -877,386.48 | -117,8% | |
| 2025-10-20 | Megna Michael R | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -13,235 | 39.31 | -520,267.85 | -69,8% | |
| 2025-10-14 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -553 | 37.99 | -21,008.47 | -2,8% | |
| 2025-10-14 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -11,815 | 37.65 | -444,834.75 | -59,7% | |
| 2025-09-29 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -42,000 | 38.33 | -1,609,860.00 | -216,1% | |
| 2025-09-15 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -16,044 | 36.45 | -584,803.80 | -78,5% | |
| 2025-09-15 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -356 | 37.00 | -13,172.00 | -1,8% | |
| 2025-09-05 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -13,389 | 35.66 | -477,451.74 | -64,1% | |
| 2025-09-04 | Moat Ross | Officer, CHIEF CORP. & COMM. OFFICER | Open Market Sale | -3,523 | 35.31 | -124,397.13 | -16,7% | |
| 2025-09-04 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -85,271 | 35.52 | -3,028,825.92 | -406,6% | |
| 2025-09-03 | Megna Michael R | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -11,000 | 34.84 | -383,240.00 | -51,4% | |
| 2025-09-03 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -15,091 | 35.50 | -535,730.50 | -71,9% | |
| 2025-08-18 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -16,100 | 33.77 | -543,697.00 | -73,0% | |
| 2025-08-18 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -100 | 34.44 | -3,444.00 | -0,5% | |
| 2025-08-14 | Malley Thomas | Director | Open Market Sale | -78,233 | 33.09 | -2,588,729.97 | -347,5% | |
| 2025-08-13 | Malley Thomas | Director | Open Market Sale | -50,129 | 33.32 | -1,670,298.28 | -224,2% | |
| 2025-08-12 | Malley Thomas | Director | Open Market Sale | -49,407 | 32.40 | -1,600,786.80 | -214,9% | |
| 2025-08-06 | Paolini John F. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -29,325 | 32.55 | -954,528.75 | -128,1% | |
| 2025-08-05 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -138,064 | 33.20 | -4,583,724.80 | -615,4% | |
| 2025-08-05 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -550 | 33.90 | -18,645.00 | -2,5% | |
| 2025-08-04 | Megna Michael R | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -17,000 | 32.35 | -549,950.00 | -73,8% | |
| 2025-08-04 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -18,889 | 32.89 | -621,259.21 | -83,4% | |
| 2025-07-14 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -18,900 | 28.72 | -542,808.00 | -72,9% | |
| 2025-06-16 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -17,300 | 28.28 | -489,244.00 | -65,7% | |
| 2025-06-11 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -45,042 | 30.51 | -1,374,231.42 | -184,5% | |
| 2025-06-11 | Quart Barry D | Director | Open Market Sale | -12,336 | 30.39 | -374,891.04 | -50,3% | |
| 2025-06-10 | Quart Barry D | Director | Open Market Sale | -8,212 | 30.36 | -249,316.32 | -33,5% | |
| 2025-06-10 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -15,506 | 30.46 | -472,312.76 | -63,4% | |
| 2025-06-09 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -10,319 | 30.38 | -313,491.22 | -42,1% | |
| 2025-06-09 | Quart Barry D | Director | Open Market Sale | -6,900 | 30.26 | -208,794.00 | -28,0% | |
| 2025-06-03 | Moat Ross | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -27,594 | 29.02 | -800,777.88 | -107,5% | |
| 2025-06-03 | Megna Michael R | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -15,211 | 28.75 | -437,316.25 | -58,7% | |
| 2025-06-03 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -18,299 | 28.80 | -527,011.20 | -70,8% | |
| 2025-05-28 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -62,116 | 27.33 | -1,697,630.28 | -227,9% | |
| 2025-05-27 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -19,317 | 27.01 | -521,752.17 | -70,0% | |
| 2025-05-23 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -4,837 | 27.00 | -130,599.00 | -17,5% | |
| 2025-05-20 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -2,349 | 27.02 | -63,469.98 | -8,5% | |
| 2025-05-19 | Tessari Eben | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -12,000 | 26.41 | -316,920.00 | -42,5% | |
| 2025-05-13 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -2,872 | 27.03 | -77,630.16 | -10,4% | |
| 2025-05-09 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -6,029 | 27.05 | -163,084.45 | -21,9% | |
| 2025-05-08 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -101 | 27.00 | -2,727.00 | -0,4% | |
| 2025-05-07 | Paolini John F. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -200 | 27.00 | -5,400.00 | -0,7% | |
| 2025-05-07 | Patel Sanj K | Director, Officer, CHAIRMAN & CEO | Open Market Sale | -1,965 | 27.00 | -53,055.00 | -7,1% | |
| 2025-05-07 | Megna Michael R | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -17,647 | 26.69 | -470,998.43 | -63,2% | |
| 2025-05-05 | Moat Ross | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -6,272 | 28.00 | -175,616.00 | -23,6% | |
| 2025-05-02 | Moat Ross | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -3,850 | 28.00 | -107,800.00 | -14,5% | |
| 2025-05-01 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -25,141 | 27.80 | -698,919.80 | -93,8% | |
| 2025-05-01 | Moat Ross | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -23,234 | 28.02 | -651,016.68 | -87,4% | |
| 2025-04-30 | Ragosa Mark | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -21,254 | 26.95 | -572,795.30 | -76,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.